Search

Displaying results 2411 - 2420 of 10000 in total
  1. Drug

    Eplontersen

    go.drugbank.com/drugs/DB16199
    ApprovedInvestigational

    +7) and the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN) Score were observed. … [A262985] As eplontersen targets both the WT and mutant TTR, it poses tremendous promises as a treatment.

  2. Drug

    Tebentafusp

    go.drugbank.com/drugs/DB15283
    ApprovedInvestigational

    [L39995] Tebentafusp was subsequently approved for the same indication in the EU in April 2022.[L41675] … [A244815] On January 26, 2022, tebentafusp was first approved by the FDA for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma.

  3. Drug

    Romidepsin

    go.drugbank.com/drugs/DB06176
    ApprovedInvestigational

    Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index
  4. Drug

    Alpha-1-proteinase inhibitor

    go.drugbank.com/drugs/DB00058
    ApprovedInvestigational

    Human alpha-1 proteinase inhibitor or alpha-1-antitrypsin, prepared from human plasma via Cohn alcohol fractionation followed by PEG and zinc chloride fractionation.

  5. Drug

    Eucalyptus globulus leaf

    go.drugbank.com/drugs/DB14320
    Approved

    Eucalyptus globulus leaf is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Mixtures: Muse Apothecary Hemp Ritual Roll On
  6. Drug

    Medifoxamine

    go.drugbank.com/drugs/DB13219
    Approved

    Medifoxamine was marketed as an atypical antidepressant, with anxiolyitc properties in France, Spain, and Morrocco in the 1990s but was later withdrawn from the market due to it causing cases of hepatotoxicity

  7. Drug

    Remestemcel-L

    go.drugbank.com/drugs/DB13973
    ApprovedInvestigationalWithdrawn

    It is estimated that the patients with the most severe forms of refractory aGvHD that do not respond to steroid therapy have expected one-year survival rates of only 5% to 30% [L11022]. … [L52008] aGvHD is a T-cell mediated disease that occurs after allogeneic hematopoietic stem cell transplant and is a reaction of donor immune cells against host tissues [A31822] developed by 30-80%

  8. Drug

    Aminosalicylic acid

    go.drugbank.com/drugs/DB00233
    ApprovedInvestigational

    An antitubercular agent often administered in association with isoniazid. The sodium salt of the drug is better tolerated than the free acid.

    Categories: Drugs for Treatment of Tuberculosis
  9. Drug

    MF101

    go.drugbank.com/drugs/DB05052
    Investigational

    MF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and menopausal women. … MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation

  10. Drug

    Chlorcyclizine

    go.drugbank.com/drugs/DB08936
    Approved

    Chlorcyclizine also has some local anesthetic, anticholinergic, and antiserotonergic properties, and can be used as an antiemetic. … Chlorcyclizine is a first generation phenylpiperazine class antihistamine used to treat urticaria, rhinitis, pruritus, and other allergy symptoms.

    Mixtures: Stahist Ad, Stahist ADInternational brands: Di-Paralene